Pulse Biosciences reaches enrollment target in atrial fibrillation study

Pulse Biosciences said its NANOPULSE-AF clinical study reached its target enrollment of 164 evaluable patients across 15 sites. The company said the study is evaluating its nPulse Cardiac Catheter System for treatment of drug-resistant, symptomatic paroxysmal atrial fibrillation.